Your session is about to expire
← Back to Search
Immunoglobulin
C-IVIG for Coronavirus
Phase 2 & 3
Waitlist Available
Led By Shaukat Ali, PhD
Research Sponsored by Dow University of Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of patients in Clinical Trial phase II/III. One Group will receive 0.15g/kg single dose of anti COVID 19 intravenously immunoglobulin (C-IVIG) develop from convalescent plasma of recovered patients from COVID 19, along with Standard of care. The Comparator group will only receive standard of Care
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
28 day Mortality
Secondary study objectives
Clinical Status of follow-up days according to 7-Catergory Ordinal Scale
Immediate and serious adverse event during hospital Stay
change in C-Reactive Protein (CRP) levels
+4 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: C-IVIGExperimental Treatment1 Intervention
The intervention group will receive the single dose of C-IVIG (0.15g/kg) with Standard of Care
Group II: ControlActive Control1 Intervention
The Control group will be receive Standard of care only
Find a Location
Who is running the clinical trial?
Dow University of Health SciencesLead Sponsor
153 Previous Clinical Trials
46,050 Total Patients Enrolled
Higher Education Commission (Pakistan)OTHER
7 Previous Clinical Trials
631 Total Patients Enrolled
Shaukat Ali, PhDPrincipal InvestigatorDow University of Health Sciences, Principal Dow College of Biotechnology
Share this study with friends
Copy Link
Messenger